Nicotinamide phosphoribosyltransferase inhibition reduces intraplaque CXCL1 production and associated neutrophil infiltration in atherosclerotic mice
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Summary: Pharmacological treatments targeting CXC chemokines and the associated neutrophil activation and recruitment into atherosclerotic plaques hold promise for treating cardiovascular disorders. Therefore, we investigated whether FK866, a nicotinamide phosphoribosyltransferase (NAMPT) inhibitor with anti-inflammatory properties that we recently found to reduce neutrophil recruitment into the ischaemic myocardium, would exert beneficial effects in a mouse atherosclerosis model. Atherosclerotic plaque formation was induced by carotid cast implantation in ApoE-/- mice that were fed with a Western-type diet. FK866 or vehicle were administrated intraperitoneally from week 8 until week 11 of the diet. Treatment with FK866 reduced neutrophil infiltration and MMP-9 content and increased collagen levels in atherosclerotic plaques compared to vehicle. No effect on other histological parameters, including intraplaque lipids or macrophages, was observed. These findings were associated with a reduction in both systemic and intraplaque CXCL1 levels in FK866-treated mice. In vitro, FK866 did not affect MMP-9 release by neutrophils, but it strongly reduced CXCL1 production by endothelial cells which, in the in vivo model, were identified as a main CXCL1 source at the plaque level. CXCL1 synthesis inhibition by FK866 appears to reflect interference with nuclear factor-κB signalling as shown by reduced p65 nuclear levels in endothelial cells pre-treated with FK866. In conclusion, pharmacological inhibition of NAMPT activity mitigates inflammation in atherosclerotic plaques by reducing CXCL1-mediated activities on neutrophils. These results support further assessments of NAMPT inhibitors for the potential prevention of plaque vulnerability.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis
Drechsler, M., Megens, R. T. A., van Zandvoort, M., Weber, C., & Soehnlein, O. (2010) · Circulation · doi:10.1161/circulationaha.110.961714 · Cited by 698 · cited 1×
“Potential rebound of other chemoattractants as a consequence of CXCL1 abrogation (34) or interference of circulating lipids on neutrophil migration (35) might explain our results on macrophage pathophysiology.”
BackgroundVan Gool, F., Gallí, M., Gueydan, C., Kruys, V., Prevot, P.-P., Bedalov, A., Mostoslavsky, R., Alt, F. W., De Smedt, T., & Leo, O. (2009) · Nature Medicine · doi:10.1038/nm.1906 · Cited by 285 · cited 6×
“Importantly, when thinking of this type of clinical applications for NAMPT inhibitors, it should be kept in mind that these agents may have significant side effects, including immunosuppressive effects (1-3).”
BackgroundInfluential
Cited by
Neutrophil Extracellular Traps in Atherosclerosis and Atherothrombosis
Döring, Y., Soehnlein, O., & Weber, C. (2017) · Circulation Research · doi:10.1161/circresaha.116.309692 · Cited by 571
Sirtuins and NAD + in the Development and Treatment of Metabolic and Cardiovascular Diseases
Kane, A. E., & Sinclair, D. A. (2018) · Circulation Research · doi:10.1161/circresaha.118.312498 · Cited by 487
Potential roles and targeted therapy of the CXCLs/CXCR2 axis in cancer and inflammatory diseases
Cheng, Y., Ma, X.-L., Wei, Y.-Q., & Wei, X.-W. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.01.005 · Cited by 344
Metabolic Insight of Neutrophils in Health and Disease
Kumar, S., & Dikshit, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02099 · Cited by 261
NAD + Metabolism in Cardiac Health, Aging, and Disease
Abdellatif, M., Sedej, S., & Kroemer, G. (2021) · Circulation · doi:10.1161/circulationaha.121.056589 · Cited by 255
Metadata
- Authors
- da Silva, R. F., Fraga-Silva, R. A., Steffens, S., Fabre, M., Bauer, I., Caffa, I., Magnone, M., Sociali, G., Quercioli, A., Pelli, G., Lenglet, S., Galan, K., Burger, F., Calvo, S. V., Bertolotto, M., Bruzzone, S., Ballestrero, A., Patrone, F., Dallegri, F., Santos, R. A. S., Stergiopulos, N., Mach, F., Vuilleumier, N., Montecucco, F., & Nencioni, A.
- Venue
- Thrombosis and Haemostasis
- Publisher
- Georg Thieme Verlag KG
- Published
- 2014
- Volume
- 112
- Issue
- 02
- Pages
- 308-322
- ISSN
- 0340-6245 (ISSN-L)
- 2567-689X
- OpenAlex
- W2098274411
- Cited by
- 51
- References
- 2
- FWCI
- 3.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.